Good Evening Market Enthusiast,
You may remember this one.
The last time it landed on our radar, the reaction was immediate…
a double-digit intraday surge.
And that wasn’t the first time.
This name has shown a habit of moving fast when attention returns.
Now it’s quietly
setting up again — but the story behind it has changed in a big way.
This is no longer a development-only biotech.
One of its therapies is already FDA-approved and already generating revenue.
In its first fiscal quarter following launch, the treatment produced $3.9 million in sales.
But that’s only one piece of the
puzzle.
Behind it sits a Phase 3 catheter infection therapy targeting a market estimated at over $1 billion in the U.S. and $2 billion globally.
And there’s a third program as well — a prescription hemorrhoid treatment currently advancing through development in a category where no FDA-approved prescription product exists today.
Three shots on
goal.
An FDA-approved therapy already on the market.
And $26.5 million invested by the founders themselves.
Meanwhile, after recently finding support earlier this month, the chart has started showing signs of life again.
Tomorrow morning at 8AM EST, we’ll release the full breakdown on why this former runner has landed back on our
radar.
⏰ Be early.
If history repeats, this one rarely moves quietly.
To your success,
Max Masters
Co-founder, Market Tips Newsletter
